Cargando…

Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study

BACKGROUND: Oclacitinib is an orally bioavailable Janus Kinase (JAK) inhibitor approved for the treatment of canine atopic dermatitis. Aberrant JAK/ Signal Transducer and Activator of Transcription (STAT) signaling within hematologic and solid tumors has been implicated as a driver of tumor growth t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barrett, Laura E., Gardner, Heather L., Barber, Lisa G., Sadowski, Abbey, London, Cheryl A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693187/ https://www.ncbi.nlm.nih.gov/pubmed/31409327 http://dx.doi.org/10.1186/s12917-019-2032-4

Ejemplares similares

Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis
por: Cosgrove, Sallie B, et al.
Publicado: (2013)

Diminished antimicrobial drug use in dogs with allergic dermatitis treated with oclacitinib
por: Mwacalimba, Kennedy, et al.
Publicado: (2023)

Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma
por: Ashton, Laura V., et al.
Publicado: (2023)

A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
por: Lopes, Natália Lôres, et al.
Publicado: (2019)

Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks
por: Panteri, Alessandro, et al.
Publicado: (2015)

Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis
por: Visser, Marike, et al.
Publicado: (2022)

A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs
por: Little, Peter R, et al.
Publicado: (2015)

A blinded, randomized, placebo‐controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel(®)) in client‐owned dogs with atopic dermatitis
por: Cosgrove, Sallie B., et al.
Publicado: (2013)

The Association Between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study
por: Rynhoud, Hester, et al.
Publicado: (2021)

The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
por: Rynhoud, Hester, et al.
Publicado: (2022)

Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib
por: Ashton, Laura V, et al.
Publicado: (2020)

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma
por: Sadowski, Abbey R., et al.
Publicado: (2018)

Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia
por: Gadeyne, Caroline, et al.
Publicado: (2014)

Comparison of Carboplatin and Doxorubicin‐Based Chemotherapy Protocols in 470 Dogs after Amputation for Treatment of Appendicular Osteosarcoma
por: Selmic, L.E., et al.
Publicado: (2014)

Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs
por: Danmaigoro, Abubakar, et al.
Publicado: (2018)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
por: Ghaferi, Mohsen, et al.
Publicado: (2022)

Effective treatment of canine chronic cutaneous lupus erythematosus variants with oclacitinib: Seven cases
por: Harvey, Richard G., et al.
Publicado: (2022)

Haematological toxicity of carboplatin in rats.
por: Siddik, Z. H., et al.
Publicado: (1987)

Serum concentration and safety of intravenous drip versus subcutaneous administration of carboplatin in dogs
por: IWANO, Masataka, et al.
Publicado: (2021)

Carboplatin, doxorubicin and etoposide in the treatment of tumours of unknown primary site
por: Piga, A, et al.
Publicado: (2004)

Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy
por: Gonzales, A J, et al.
Publicado: (2014)

Inherited Sensory and Autonomic Neuropathy in a Border Collie, Interest of Oclacitinib for the Control of Self-Mutilation
por: Leonard, Caroline, et al.
Publicado: (2022)

Evaluation of topical oclacitinib and nail trimming as a treatment for murine ulcerative dermatitis in laboratory mice
por: Davison, Steven E., et al.
Publicado: (2022)

Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011‐2016) and comparison with doxorubicin‐based chemotherapy
por: Faulhaber, Erica A., et al.
Publicado: (2021)

The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro
por: Marley, Kevin, et al.
Publicado: (2013)

Erratum for “Adjuvant carboplatin for treatment of splenic hemangiosarcoma in dogs: Retrospective evaluation of 18 cases (2011‐2016) and comparison with doxorubicin‐based chemotherapy”
Publicado: (2021)

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
por: London, Cheryl A., et al.
Publicado: (2015)

Pharmacokinetics and toxicity of subcutaneous administration of carboplatin in poloxamer 407 in a rodent model pilot study
por: Risselada, Marije, et al.
Publicado: (2017)

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)
por: Kim, Kenneth H., et al.
Publicado: (2015)

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
por: Helbekkmo, N, et al.
Publicado: (2007)

Fatal disseminated toxoplasmosis in a feline immunodeficiency virus‐positive cat receiving oclacitinib for feline atopic skin syndrome
por: Moore, Alexandra, et al.
Publicado: (2022)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Prevotella copri is associated with carboplatin-induced gut toxicity
por: Yu, Chaoheng, et al.
Publicado: (2019)

Evaluation of carboplatin sustained‐release delivery system in dogs with cancer
por: Tansey Baldwin, Colleen, et al.
Publicado: (2016)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Complete remission of two canine cases with precursor-targeted immune-mediated anemia after combination therapy with prednisolone, cyclosporine, and oclacitinib
por: Yuki, Masashi, et al.
Publicado: (2023)

A retrospective evaluation of the effect of oclacitinib (Apoquel) administration on development of surgical site infection following clean orthopedic stifle surgery
por: Motz, Alyssa K., et al.
Publicado: (2023)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Evaluation of Weight Change During Carboplatin Therapy in Dogs With Appendicular Osteosarcoma
por: Story, A.L., et al.
Publicado: (2017)

Ocular toxicity following carboplatin chemotherapy for neuroendocrine tumour of the bladder
por: Ng, Jia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3heqd1ue0kjobjncqciju5pii2